Navigation Links
Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Date:9/15/2008

cle also highlighted the second tumor-targeted agent in development by Epeius Biotechnologies, describing Reximmune-C as an immune stimulant, or personalized cancer vaccine, designed to be used alone or in combination with Rexin-G. Reximmune-C incorporates a powerful cytokine gene, in place of the cytocidal gene used in Rexin-G, to deliver an immune- stimulating pulse to activate a patient's own immune cells in the area of residual tumors to prevent recurrence. Remarkably, several of the prominent cancer researchers, companies, and academicians interviewed for the JNCI article focused-in principle-on the very same issues that Epeius Biotechnologies, with its definitive molecular engineering platform, has actually managed to address. The JNCI article is well worth reading.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies that are currently available for licensing and clinical development, please visit our website, http://www.epeiusbiotech.com.

For more information about Rexin-G, Reximmune-C, and on-going clinical trials in the USA and abroad, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(Logo Link: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
4. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
5. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
6. MacroGenics Acquires Raven Biotechnologies
7. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
8. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
9. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
... cheaper and more efficient is the aim of a ... and Q1 NanoSystems. The university and the company, based ... exclusive licensing of a package of jointly-owned intellectual property ... The agreement covers inventions that enable manufacture of very ...
... GPRO ) announced today that the Company will ... on Wednesday, February 13,2008 at approximately 4:00 p.m. Eastern ... call at 4:30 p.m. ET hosted by Henry L. ... senior,vice president, finance, and chief financial officer., The ...
Cached Biology Technology:Pharmaxis' Aridol Gains First Asian Approval 2Solar energy technology licensed 2Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call 2
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis could ... that act against various bacteria, fungal infections and parasites, ... of Illinois chemists and collaborators. , Led by U. ... the different ways the drug SQ109 attacks the tuberculosis ... other pathogens from yeast to malaria and how ...
(Date:4/17/2014)... 2014. Kessler Foundation has been named awardee of ... Department of Defense Spinal Cord Injury Research Program. ... the randomized, double-blinded, controlled, multi-site clinical trial, which ... strength after spinal cord injury. Dr. Forrest is ... at Kessler Foundation. Two additional sites will participate ...
(Date:4/17/2014)... Down syndrome - or trisomy 21 - is the ... from a chromosomal abnormality where cells of affected individuals ... the human genome). A study conducted by Stylianos Antonarakis ... and Development at the University of Geneva (UNIGE) Faculty ... on how the extra chromosome 21 upsets the equilibrium ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... is fit and well? This is a question which has ... have come up with the answer - using DNA chips. ... UK universities are developing a DNA chip to monitor the ... save the salmon industry thousands and also help conserve dwindling ...
... notable effect on rates of pregnancy and abortion, according to ... emergency contraception is questioned by Professor Anna Glasier, director of ... NHS Trust, Edinburgh, who says it does help some women ... pregnant. , Use of this form of contraception has increased ...
... broccoli was good for you, she just didn't know it ... you and that it contains compounds known to lessen the ... how these compounds work and what their specific targets may ... at the University of Virginia School of Medicine. , ...
Cached Biology News:Special chip provides better picture of salmon health 2Special chip provides better picture of salmon health 3
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... Ciphergens ProteinChip System, Series 4000 incorporates the ... researchers and biologists in biomarker research. The ... fastest route for converting biomarker discoveries to ... The Series 4000 is designed to fit ...
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
Biology Products: